PDCD1 and cancer: Immune checkpoint inhibitors, including anti-programmed cell death 1 (PD-1), anti-programmed cell death ligand 1 (PD-L1) monoclonal antibodies (MAbs) and CTL-associated antigen 4 (CTLA4) blockade have been confirmed to improve the overall survival rate of patients in different cancer types (11, 12).